The L-plastin protein: structure and function Plastins belong to the class of actin-bundling proteins. In mammals, three plastin isoforms have been discovered: T-plastin is expressed in cells derived from solid tissue, I-plastin is specifically expressed in microvilli of the small intestine and the kidney, and L-plastin expression is found in cells of the hematopoetic lineage (leukocytes). The three plastin isoforms share around 70% homology of their amino acid sequences but are encoded by individual genes located on different chromosomes (Lin et al., 1993b) . Plastins have a common domain structure consisting of two amino-terminal EF-hands, implicated in calcium-binding, followed by two tandem actin-binding domains, each composed out of two calponin homology (CH) domains (de Arruda et al., 1990) (Fig. 1) .
The fact that L-plastin possesses two amino-terminal calcium-binding domains (de Arruda et al., 1990) suggests that the actin-binding properties of L-plastin are regulated by calcium. Indeed, L-plastin bundels actin filaments in vitro in a calcium-dependent manner (Namba et al., 1992) . L-plastin is the only plastin isoform for which phosphorylation in response to a variety of stimuli has been demonstrated in different cell types (Matsushima et al., 1987; Shiroo and Matsushima, 1990; Shibata et al., 1993; Henning et al., 1994; Jones and Brown, 1996) . A number of experiments performed with macrophages and polymorphonuclear neutrophils (PMN) point to a role for L-plastin in regulating integrin mediated adhesion (Messier et al., 1993; Jones et al., 1998; Correia et al., 1999; Wang et al., 2001) . Despite this, PMN derived from an L-plastin knock-out mouse were only defective in generating the respiratory burst, but showed normal morphology, adhesion, spreading, migration and phagocytosis (Chen et al., 2003) . This latter finding may, however, result from redundancy in the function of actin-binding proteins.
Expression and function of L-plastin in human cancer cells
More than 20 years ago it was noticed that L-plastin is upregulated during chemically induced malignant transformation of human fibroblasts (Leavitt and Kakunaga, 1980; Leavitt et al., 1982) . Indeed, L-plastin expression was found in 68% of epithelial , two calcium-binding domains of the EF-hand type, and two tandemly organized actin-binding domains each composed out of two calponin-homology (CH) domains. PKA-motif: protein kinase A (EC 2.7.11.1) phosphorylation consensus sequence.
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carcinomas and 53% of non-epithelial mesenchymal tumors (Lin et al., 1993b) . Moreover, examination of a variety of human tumor cell lines revealed that more than 90% displayed varying degrees of constitutive L-plastin expression (Park et al., 1994) .
L-plastin expression does not correlate with tumor stages in breast carcinomas
The analysis of L-plastin expression in normal breast tissues by immunohistochemistry and immunoblotting revealed that L-plastin expression could be detected in normal myoepithelial cells but not in untransformed epithelial cells of the mammary gland (Lapillonne et al., 2000) . In breast carcinomas, L-plastin was detected in malignant epithelial cells in around 14% of the tumors analyzed. However, no correlation between L-plastin expression and tumor size, histological grade or lymph node status was observed (Lapillonne et al., 2000) . Functional data using breast carcinoma cell lines were so far not presented.
Expression of an L-plastin antisense gene reduced invasion of prostate carcinoma cells L-plastin expression was observed in several prostate carcinoma cell lines, but not in a normal prostate epithelial cell line (Zheng et al., 1997) . RT-PCR analysis of normal and tumor tissues of the same prostate gland revealed that prostate tumor tissues exhibit a higher level of L-plastin expression compared to normal tissue (Zheng et al., 1997) . However, RT-PCR analysis of tissues does not allow to discriminate between L-plastin expressing cells and L-plastin expressing tissue infiltrating leukocytes. Immunohistochemical analysis demonstrated, that L-plastin is predominately expressed in carcinomatous glandular epithelial cells, whereas L-plastin expression was not detected in the glandular epithelial cells of normal prostate (Zheng et al., 1997) . Whether L-plastin expression correlates with tumor stages was not adressed in these studies.
Expression of an L-plastin antisense gene in the prostate carcinoma cell line PC-3 and its isogenic but metastatic variant PC-3M reduced the growth rates as well as invasion and motility of both cell lines (Zheng et al., 1999) . These data indicated that L-plastin overexpression might be involved in prostate cancer invasion. However, the finding that both cell lines, the low metastatic variant PC-3 as well as the high metastatic variant PC-3M, expressed L-plastin makes it difficult to draw general conclusions from the antisense L-plastin experiment.
The amount of L-plastin expression correlates with tumor stages in human colorectal cancer
The colon carcinoma cell lines SW480 and SW620 provide a well known model system to study genetic changes in colon cancer progression. SW480 was established from a primary colon adenocarcinoma and SW620 was established one year later from a lymph node metastasis of the same patient (Semple et al., 1978) . Microarray analysis of these two cell lines revealed that in the metastasis-derived SW620 cells the expression of two genes was decreased, whereas the expression of 6 genes was increased compared to the primary tumor-derived SW480 cells. Amongst the 6 upregulated genes was L-plastin (Otsuka et al., 2001) . Expression of L-plastin was further investigated by immunhistochemical analysis of a tissue microarray consisting of 58 colorectal cancer specimens with known tumor stages. L-plastin staining was either absent or weak in stage II tumor tissues, whereas a moderate or strong staining was seen in stage III and IV tumor tissues (Otsuka et al., 2001) . It was concluded that the amount of L-plastin expression may represent a potential metastasisrelated biomarker.
The SW480 and SW620 colon cancer cell line system was used for further investigations on the function of L-plastin in colon carcinoma cells. When L-plastin was overexpressed in the primary tumor-derived cell line SW480, cells displayed higher rates of proliferation and invasion than normal SW480 cells. In addition, the expression of E-cadherin was lost (Foran et al., 2006) . Given that SW620 cells-originally derived from a metastasis of this tumor-, express high endogenous levels of L-plastin and E-cadherin (Foran et al., 2006) , the influence of L-plastin on the expression of E-cadherin remains an open question.
Phosphorylation of ectopically expressed L-plastin is required to enhance the invasiveness of human melanoma cells
Recently, we demonstrated by immunohistological analysis that L-plastin is expressed in 25% of human malignant melanoma specimens derived from patients. However, L-plastin expression did not correlate with tumor stages or penetration depths (Klemke et al., 2007) . Still, esiRNA-mediated knock-down of L-plastin in a human melanoma cell line negatively influenced cell migration. One possibility to explain this finding was that, besides expression of L-plastin, other factors are needed to promote metastasis of human melanoma cells. A number of findings in hematopoetic cells pointed to the fact that L-plastin is regulated by phosphorylation (Matsushima et al., 1987; Shiroo and Matsushima, 1990; Shibata et al., 1993; Henning et al., 1994; Jones and Brown, 1996) . Therefore, phosphorylation of L-plastin was a candidate factor influencing the function of L-plastin in human tumor cells.
We investigated whether phosphorylation of L-plastin may influence the adhesiveness, the motility and invasiveness of human melanoma cells, key features of metastasis. To this end, the L-plastin negative human melanoma cell line MV3 was stably transfected with either EGFP (control cells), wild-type L-plastin fused to EGFP (wt-L-plastin), or a mutated version of L-plastin, in which the known phosphorylation sites of L-plastin, Ser5 and Ser7 (Lin et al., 1998) (Fig. 1) were changed to non-phosphorylatable Ala (5A7A-Lplastin). Using 2D-gel-electrophoresis we first showed that in MV3 cells wt-L-plastin undergoes spontaneous phosphorylation, which was not observed in cells expressing 5A7A-L-plastin (Klemke et al., 2007) . MV3 cell populations stably expressing wt-L-plastin or non-phosphorylatable 5A7A-L-plastin showed no change in static adhesion to collagen I and fibronectin. However, in a haptotactic migration assay, both wt-L-plastin and 5A7A-L-plastin expressing cells migrated faster towards collagen I and fibronectin than the control cells (Klemke et al., 2007) . Thus, L-plastin enhances haptotactic migration independent of its phosphorylation state. Note that differences in the migratory behavior of wt-L-plastin, 5A7A-L-plastin or control cells were not observed in a chemotactic migration assay. Given the fact that wt-L-plastin and 5A7A-L-plastin expressing cells reached their maximal migration speed already during haptotaxis without the need for additional chemotactic signals, especially in the absence of chemotactic stimuli the expression of L-plastin may decide whether tumor cells rapidly colonialize distant tissues.
In addition to tumor cell detachment and cell migration, during the process of metastasis tumor cells need to penetrate basement membranes to invade tissues or lymph vessels. Interestingly, with regard to tumor cell invasiveness, wt-L-plastin expressing melanoma cells behaved differently from cells expressing the non-phosphorylatable 5A7A-L-plastin. Although 5A7A-L-plastin expressing cells and control cells were to a certain extent able to invade the Matrigel layer, an up to threefold increase occurred, if cells expressed phosphorylatable wt-L-plastin (Klemke et al., 2007) . Thus, not only expression but also phosphorylation of L-plastin is required to enhance tumor cell invasiveness. In accordance with this notion, mouse B16F10 melanoma cells, which show high metastasis in vivo (Fidler, 1974; Fidler et al., 1976) , expressed high amounts of L-plastin which undergoes phosphorylation, whereas this is not the case in the low metastatic mouse B16F1 melanoma cells.
The exact molecular mechanisms of how non-phosphorylated L-plastin enhances migration and how phosphorylated L-plastin enhances both migration and invasion are not known. Given the lack of changes in the adhesiveness to b1-integrins upon L-plastin expression, it is likely that expression and phosphorylation of L-plastin influence postadhesive integrin induced signaling events leading to rearrangements of the actin cytoskeleton required for enhanced migration and invasion.
The fact that only phosphorylated L-plastin promotes tumor cell invasiveness would explain the observed lack of correlation between L-plastin expression and tumor progression in some but not all types of tumors, because none of these studies considered the phosphorylation state of L-plastin. Therefore, in the future, not only the expression of L-plastin but also the phosphorylation status of L-plastin should be compared with regard to tumor progression. Besides the potential prognostic relevance of L-plastin expression and phosphorylation in human cancer cells, L-plastin may also represent a novel target for cancer therapy. Reduction of L-plastin expression and/or phosphorylation in tumor cells may interfere with tumor cell migration and invasion and, hence, reduce metastasis.
New tools for gene therapy of cancer based on constitutive activity of the L-plastin promotor in cancer cells
The constitutive expression of L-plastin in many types of malignant human cells of solid tissues suggests that activation of the L-plastin promotor represents a frequently occurring process during tumorigenesis. Accordingly, in transformed cells that express L-plastin constitutively transfection of a promotor construct containing the upstream regulatory elements, the TATAAA-box, and part of the first exon of L-plastin led to constitutive expression of the reporter gene b-galactosidase (EC 3.2.1.23). In contrast, this promotor was inactive in normal fibroblasts as well as in fibroblasts which were SV40-transformed in vitro and which did not exhibit L-plastin expression (Lin et al., 1993a) . These data indicated that the L-plastin promotor may be used to specifically drive the expression of genes in L-plastin expressing tumors for therapeutic purposes.
To test this hypothesis, a replication-deficient recombinant adenoviral vector was generated, which contained the human L-plastin promotor driving the E.coli LacZ gene (Chung et al., 1999) . Because adenoviral vectors infect L-plastin expressing hematopoetic cells only poorly, this vector would target mainly non-hematopoetic cells. Thus, expression should be restricted to L-plastin expressing non-hematopoetic tumor cells. Indeed, following adenoviral infection, expression of the LacZ gene was only observed in breast and ovarian cancer cell lines as well as in a fibrosarcoma cell line, but not in normal fibroblasts and hematopoetic cells such as U937 leukemia cells (Chung et al., 1999) . These results suggested that also in organisms infected with adenoviral vectors carrying the L-plastin promotor transcription of (therapeutic) genes should be restricted to L-plastin positive tumor cells.
Meanwhile, several experimental approaches employing this strategy led to promising results. Cytosine deaminase (EC 3.5.4.1) catalyzes the conversion of the harmless prodrug 5-fluorocytosine into the toxic agent 5-fluorouracil. Indeed, a replication-incompetent adenoviral vector carrying a truncated L-plastin promotor upstream of the cytosine deaminase gene made ovarian-, breast-and colon-cancer cell lines much more sensitive to the prodrug 5-fluorocytosine than a minimal deviation fibroblast cell line or normal mammary epithelial cells after exposure to the same vector. Moreover, expression of this vector prevented engraftment of ovarian cancer cells in 5-fluorocytosine treated nude mice (Peng et al., 2001) . A similar adenoviral vector carrying the cytosine deaminase gene as well as the EA1 gene, which is necessary for viral replication, under the control of a truncated L-plastin promotor was effectively used to enhance killing of cancer cells by 5-fluorouracil (Akbulut et al., 2003 (Akbulut et al., , 2004 . In a mouse model of epithelial neoplasms in the presence of this adenoviral vector the doses of 5-fluorouracil in a combination chemotherapy (CPT-11, folinic acid and 5-fluorouracil) could be reduced, resulting in lower toxicity and increased efficacy as compared to the conventional combination chemotherapy (Akbulut et al., 2004) . This concept-based on vectors driven by the L-plastin promotor-therefore seems promising for the development of new strategies for the treatment of cancer.
Conclusion
Based on the data described above, we propose the following model of L-plastin function in tumor progression (Fig. 2) : Expression of L-plastin leads to enhanced cell migration towards extracellular matrix components. However, mere expression of L-plastin does not promote tumor cell invasion into basement membranes. Only, if L-plastin is phosphorylated, either by proper signalling events from the tumor cell environment, or by constant activation of signal transduction pathways in the course of cell transformation, tumor cell invasion and, hence, metastasis is promoted. This would
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adhesion migration invasion L-plastin no effect enhanced no effect phospho-L-plastin no effect enhanced enhanced explain the observed lack of correlation between L-plastin expression and tumor progression in some but not all types of tumors, since none of these studies considered the phosphorylation state of L-plastin. Therefore, in the future, not only the expression of L-plastin but also the phosphorylation status of L-plastin should be compared with regard to tumor progression. Moreover, in-depth molecular data are missing showing how L-plastin exactly functions in tumor cells and which signaling molecules are involved in regulation and phosphorylation of L-plastin. Besides that, the observed selective activation of the L-plastin promotor in transformed-but not untransformed-non-hematopoetic cells has interesting implications for gene therapy of cancer.
Summary
Modulation of the actin cytoskeleton is critical for tumor cell migration and invasion. Therefore, actin-binding proteins which regulate this modulation may be valuable targets to inhibit the metastatic properties of tumor cells. Changes in the actin cytoskeleton are accomplished by a variety of actin-binding proteins such as cofilin, a-actinin, filamin, fascin and the plastins. Interestingly, the hematopoetic isoform of the plastins, L-plastin, is not only expressed by hematopoetic cells, but also by most human cancer cell lines. Yet, data regarding the functional importance of L-plastin expression in tumor tissues are controversial: in colon carcinomas, the expression level of L-plastin correlated with tumor progression, whereas no such correlation could be seen in breast carcinomas. We therefore systematically investigated whether expression of L-plastin influences the adhesiveness, the motility and invasiveness of human tumor cells. An siRNA mediated knock-down of L-plastin in an L-plastin positive melanoma cell line inhibited migration of these cells. Accordingly, expression of L-plastin in L-plastin negative melanoma cells led to enhanced cell migration towards extracellular matrix components. However, mere expression of L-plastin did not promote tumor cell invasion into basement membranes. Only, if L-plastin was phosphorylated, tumor cell invasion was promoted. Therefore, in clinical studies, not only the expression of L-plastin but also the phosphorylation status of L-plastin should be compared with regard to tumor progression.
Besides the potential prognostic relevance of L-plastin expression and phosphorylation in human cancer cells, L-plastin may represent a novel target for cancer therapy. Moreover, the constitutive activity of the L-plastin promotor in non-hematopoetic tumors opens up novel perspectives for gene therapy of cancer using L-plastin-promotor driven viral vectors.
